Basf Se Corporation

Metanomics Gmbh

Jan C Wiemer

Edgar Leibold

Ralf Looser

Tilmann B Walk

Michael Manfred Herold

Werner Mellert

Georgia Coelho Palermo Cunha

Alexandre Prokoudine

Bennard Van Ravenzwaay

Eric Fabian

Volker Strauss

Hennicke Kamp

Bianca Bethan

Kristina Busch

Thomas Ehrhardt

Volker Haake

Martijn Gipmans

Jochen Spranger

Thomas Bobbert

Andreas Friedrich Hermann Pfeiffer

Beate Kamlage

Oliver Schmitz

Gerhard Krennrich

The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection including characteristic values of at least five metabolites, a data storage medium including data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

Means and methods for assessing increased peroxisomal proliferation

The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing the pro-pathological effect of compounds which are inducing liver enzymes. It also relates to a method of determining whether a compound is capable of exhibiting pro-pathological effects on the liver by enzyme induction in a subject and to a method of identifying a drug for treating the pro-pathological effect of liver enzyme induction. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five analytes, a data storage medium comprising said data collection, and a system and a device for diagnosing the pro-pathological effect of liver enzyme induction. Finally, the present invention pertains to the use of a group of analytes or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing the pro-pathological effect of liver enzyme induction in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed. The liver enzyme induction markers are mainly selected from free fatty acids, but also include various phosphatidylcholines, galactose, 3- and 5-Methoxysphingosine, Cholesterol, Threonic acid, 1,2-Dioleoyl-sn-glycero-3-phosphatidyl-L-serine, Glycerol, Glycerophosphate, Dodecanol, myo-Inositol-2-monophosphate.

Methods related to liver enzyme induction as a predisposition for liver toxicity and diseases or disorders associated therewith

The present invention pertains to the field of toxicological assessments of risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection of characteristic values of at least five metabolites, a data storage medium for the data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject.

The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing liver toxicity. It also relates to a method of determining whether a compound is capable of inducing such liver toxicity in a subject and to a method of identifying a drug for treating liver toxicity. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing liver toxicity. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing liver toxicity in a subject. For each sex, a different metabolome pattern, i.e. a different set of analytes is disclosed. The liver toxicity markers are mainly selected from free fatty acids, but also include various phosphatidylcholines, Hydroxyphenylpyruvic acid, alpha-Tocopherol, Cholesterol, myo-Inositol-2-monophosphate, 4-Hydroxysphinganine, Ceramide (d18:1, C24:1), Ceramide (d18:2, C24:0), Sphingomyelin (d18:1, C16:0), 1,2-Dioleoyl-sn-glycero-3-phosphatidyl-L-serine, 18:1 Lyso Phosphatidylcholine, Coenzyme Q9, Glucose, Glycerol, Glycerophosphates, Phosphate, 5-Methoxysphingosine, erythrosphingosine, Threonine, Diacylglycerides and Triacylglycerides.

Method for diagnosing liver toxicity with sex specific biomarkers

The present invention relates to a method for diagnosing hemolytic anemia or a predisposition thereof. It also relates to a method of determining whether a compound is capable of inducing hemolytic anemia in a subject and to a method of identifying a drug for treating hemolytic anemia. Furthermore, the present invention relates to a data collection comprising characteristic values of metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing hemolytic anemia. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing hemolytic anemia in a subject.

Means and method for diagnosing hemolytic anemia

The present invention relates to a method for diagnosing diabetes or a predisposition thereof, comprising determining at least one metabolite in a test sample of a subject suspected to suffer from diabetes or to have a predisposition therefor and comparing the metabolite to a reference to diagnose diabetes or a predisposition therefor. The present invention further encompasses a collection of metabolites, a data collection comprising characteristic values of metabolites and a storage medium comprising the data collection. The present invention also relates to a system comprising methods or devices for comparing characteristic values of metabolites of a sample operatively linked to a data storage medium. The present invention also encompasses diagnostic methods or devices comprising at least one metabolite and use of the metabolite for the manufacture of diagnostic methods and devices for diagnosing diabetes; and a method for identifying diabetes-related metabolites.

Means and method for diagnosing diabetes

The present invention relates to a method for diagnosing a predisposition for diabetes, comprising determining a metabolite in a test sample of a subject suspected to have a predisposition for diabetes and comparing the metabolite to a reference to diagnose the, predisposition for diabetes. Moreover, the present invention encompasses a collection of metabolites, a data collection comprising characteristic values of metabolites and a storage medium comprising the data collection. The present invention also relates to a system comprising methods or devices for comparing characteristic values of metabolites of a sample operatively linked to a data storage medium. Additionally, diagnostic methods or devices comprising a metabolite and its use for manufacture of the diagnostic method or device for diagnosing a predisposition for diabetes are provided, along with a method for identifying diabetes-related metabolites.

Means and method for predicting diabetes

A method for analyzing a test sample is disclosed, the test sample comprising at least one compound. A test sample comprising at least one compound is provided. Next, the at least one compound in the test sample is determined, thereby generating raw results. The generated raw results are analyzed, wherein the analysis of the test sample is accompanied by an analysis of at least one reference sample. The test sample and the reference sample are analyzed in an identical sequence in each step of the method. A system for carrying out the method is also disclosed.

System and method for analyzing a sample using chromatography coupled mass spectrometry

Growing community of inventors

Berlin, Germany

Jan C Wiemer